Then, understanding whether MCT1 and MCT4 represent new therapeutic targets and whether their inhibitors AR-C and SYRO can be used in leukemia therapy, may reveal an alternative treatment strategy in patients with AML. Here, SLC16A3 is linked to leukemia.